The FDA has is­sued a com­plete re­sponse let­ter to John­son & John­son for the sub­cu­ta­neous ver­sion of its lung can­cer drug Ry­bre­vant af­ter is­sues were … ...

Johnson & Johnson has received coal in its stocking from the FDA as manufacturing issues have tripped up the company’s attempt to gain approval of its subcutaneous version of lung cancer drug ...